Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma.

ABSTRACT:

Background

The addition of procarbazine, lomustine, vincristine (PCV) chemotherapy to radiotherapy (RT) for patients with high-risk (≥40 y old or subtotally resected) low-grade glioma (LGG) results in an absolute median survival benefit of over 5 years. We evaluated the cost-effectiveness of this treatment strategy.

Methods

A decision tree with an integrated 3-state Markov model was created to follow patients with high-risk LGG after surgery treated with RT versus RT+PCV. Patients existed in one of 3 health states: stable, progressive, or dead. Survival and freedom from progression were modeled to reflect the results of RTOG 9802 using time-dependent transition probabilities. Health utility values and costs of care were derived from the literature and national registry datab

SUBMITTER: Qian Y 

PROVIDER: S-EPMC5716167 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature